Trade talks between the United Kingdom and Switzerland are facing delays due to a growing disagreement over pharmaceutical rules. The two countries have been negotiating an upgraded free trade deal since 2023, but recent discussions have slowed down because of differences over drug patent protections.
At the heart of the issue is a system known as a Supplementary Protection Certificate (SPC), which allows pharmaceutical companies to extend patent rights beyond the usual 20 years. Switzerland wants these protections to be clearly included in the new trade agreement, ensuring long-term security for its strong pharmaceutical industry.
However, the UK government is hesitant. Officials are worried that agreeing to these terms could lead to higher medicine prices, putting extra pressure on the National Health Service (NHS). The concern is that longer patent periods would delay cheaper generic drugs from entering the market.
The disagreement has also created divisions within the UK government. The Department of Health is pushing back against the proposal due to cost concerns, while trade and business departments are more open to the idea, saying it could boost innovation and attract investment in the pharma sector.
With both sides holding firm, the future of the trade deal remains uncertain unless a compromise is reached.
Why this matters:
This dispute could delay an important trade agreement between two major economies. It also highlights the ongoing challenge of balancing affordable healthcare with support for pharmaceutical innovation.